[June 24, 2016] |
|
Sosei Appoints Peter Bains as CEO
Sosei Group Corporation ("Sosei"; TOKYO Mothers Index: 4565) today
announces the appointment of Mr Peter Bains as Representative Executive
Officer and Chief Executive Officer (CEO) effective from June 24 2016
upon approval by the Board of Directors following Sosei Group's Annual
General Meeting. At the same time, Mr Shinichi Tamura, Sosei founder and
Group Chairman, President and CEO, is appointed as Representative
Executive Officer and Executive Chairman. Peter Bains will continue to
report to Mr Shinichi Tamura.
1.
|
|
The reason for appointment
|
|
|
To further strengthen/develop the system of management to improve
our corporate value and reinforce the management base
|
|
2.
|
|
The name and title of Representative Executive Officer
|
|
|
Name:
|
Peter Bains
|
|
|
Title:
|
Representative Executive Officer and Chief Executive Officer (CEO)
|
|
3.
|
|
Brief summary of Peter Bains
|
|
|
Date of birth
|
|
Profile
|
|
Ownership of shares of Sosei
|
|
|
July 26 1957
|
|
March 1996: General Manager of SmithKline Beecham plc.
(GlaxoSmithKline)
|
|
0
|
|
|
|
January 2001: Senior Vice President, GlaxoSmithKline International
Commercial Development
|
|
|
|
|
June 2009: Director of Peter Bains Consulting Limited.
|
|
|
|
|
January 2010: Non-executive Board Director at Syngene International
Limited
|
|
|
|
|
June 2010: Non-executive Director at Sosei Group Corporation
|
|
|
|
|
February 2015: Director at Heptares Therapeutics Ltd.
|
|
|
|
|
February 2015: Executive Director and CEO at Syngene International
Limited
|
|
|
|
|
April 2016:Representative Executive Officer and Chief Operating
Officer at Sosei Group Corporation
|
|
|
4.
|
|
Effective date
|
|
|
As of June 24 2016
|
|
About Sosei Sosei Group Corporation is an international
biopharmaceutical company originating from Japan that discovers and
develops innovative biopharmaceuticals for the treatment of Alzheimer's
disease, schizophrenia, cancer, migraine, addiction, metabolic disease,
and other indications. By utilizing its GPCR structure-based drug design
platform technology, Sosei have established a product pipeline with
first/best in class potential. Through development and commercialization
partnerships, Sosei have already delivered two bronchodilators for COPD
which generate significant and stable revenue streams that enable
further growth. Sosei partners include Novartis, Allergan, AstraZeneca,
MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for
new partnerships to enhance the development of our products and help us
deliver them to patients worldwide.
For further information about Sosei, please visit www.sosei.com/en.
Forward-looking statements This press release contains
forward-looking statements, including statements about the discovery,
development and commercialisation of products. Various risks may cause
Sosei's actual results to differ materially from those expressed or
implied by the forward-looking statements, including: adverse results in
clinical development programmes; failure to obtain patent protection for
inventions; commercial limitations imposed by patents owned or
controlled by third parties; dependence upon strategic alliance partners
to develop and commercialise products and services; difficulties or
delays in obtaining regulatory approvals to market products and services
resulting from development efforts; the requirement for substantial
funding to conduct research and development and to expand
commercialisation activities; and product initiatives by competitors. As
a result of these factors, prospective investors are cautioned not to
rely on any forward-looking statements. We disclaim any intention or
obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160624005208/en/
[ Back To TMCnet.com's Homepage ]
|